ArticleJournal of diabetes and metabolic disorders2025
Nobiletin can play a role in improving inflammation by inhibiting the NF-kB and MAPK pathways in muscle cells.
Article in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nobiletin as a Geroprotective Flavonoid: Mechanisms of Action, Therapeutic Potential, and Challenges of Bioavailability.Antioxidants (Basel, Switzerland) · 2026Review
- Targeting the NF-κB Pathway in Cancer: Mechanisms, Resistance, and Therapeutic Potential Across Tumor Types.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Potential and Mechanism of Nobiletin in Diabetes Mellitus and Associated Complications.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Insulin resistance and inflammation plays a major role in the pathogenesis of metabolic diseases such as diabetes and metabolic syndrome. Increased circulating fatty acids and inflammatory cytokines are among the most important factors that induce inflammation and subsequent insulin resistance. Studies indicate that fatty acids, especially palmitate, play a role in inducing inflammation and increasing inflammatory cytokines such as TNF-ɑ and IL-6 and stimulating the NF-kB and MAPK (especially JNK) signaling pathways. Nobiletin (Nob) as a natural polyphenol has anti-diabetic and anti-inflammatory effects. However, its mechanism in muscle cells is unclear, which was addressed in this study. Materials and methods: The increase in inflammatory cytokines TNF-ɑ and IL-6 caused by palmitate was evaluated by Real-time PCR. The expression of NF-kB and JNK proteins caused by palmitate was also measured by Western blotting. The effect of Nob on cytokines and inflammatory pathways in palmitate-treated C2C12 cells was assessed by Real-time PCR and Western blotting. Intracellular ROS levels were also measured using the DCFH-DA probe. Results: Palmitate significantly increased the expression and secretion of inflammatory genes TNF-α, IL-6, and IL-1β and the phosphorylation of NF-KB and JNK in muscle cells, and in contrast, nobiletin at a concentration of 100 µM significantly decreased the expression of inflammatory genes TNF-α, IL-6, and IL-1β and the phosphorylation of NF-KB and JNK in muscle cells treated with palmitate. Intracellular ROS levels were increased by palmitate, which was reduced by nobiletin treatment, but this decrease was not statistically significant. Conclusion: This study showed that the beneficial anti-inflammatory effects of nobiletin in muscle cells are accompanied by suppression of ROS production and reduction of MAPK activity (especially JNK) and inhibition of the NF-kB signaling pathway. We introduce nobiletin as a potential anti-inflammatory and anti-diabetic natural compound so that its therapeutic effects can be further studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.